Through development of selected bacterial glycoconjugate vaccines, GlycoVaxyn is generating a pipeline of significant interest to the vaccine community and is demonstrating, technically and clinically, the potential of its technology. GlycoVaxyn selects its pipeline with a view to rapidly generating and maximising value while minimising risk. Each candidate must have a medical need and market opportunity, offer significant advantages over any existing approaches to management of a disease, and preferably have development milestones permitting early proof-of-concept.
Figure 4: Product development plan
By addressing unmet medical needs, such as the lack of vaccines against several pathogens (e.g. Men B, ExPEC) and the challenge of covering the dozens of S. Pneumoniae serotypes, GlycoVaxyn’s product pipeline offers major opportunities for companies that either, need to rejuvenate their pipeline, or intend to enter the vaccine market.
For example, the company’s S.aureus program represents an interesting opportunity in a market where other programs have failed and where the company has obtained encouraging protection data in animal models.
The company’s earlier stage programs, N. meningitis B and S. pneumoniae, also represent major value creation opportunities in which the efficacy of the conjugate will be obtained in a preclinical model, followed by a phase I clinical trial. In case of S. pneumoniae, the the efficacy will be benchmarked against the existing marketed vaccine, therefore an early clinical proof of concept can be established, thus paving the way for the rapid development of the vaccine.
Beyond these more advanced programs, the technology has broader potential applications in the fields of bacterial vaccines, including P. aeruginosa, Extraintestinal Pathogenic E. coli (ExPEC), Group A Streptococcus (GAS) and Enterotoxigenic E. coli (ETEC), which have all already been synthetized in the laboratory.
